label version or jurisdiction
International <50 threshold versus NIH U.S.-focused <30 position
The KIVEXA source advises against the fixed product below CrCl 50. NIH distinguishes U.S.-focused ABC/3TC guidance below 30 and qualified panel-member continuation practices with insufficient evidence.
What to reconcileConfirm market, exact formulation and the controlling label. The panel practice is not blanket initiation approval; preserve the source-specific lamivudine qualification.
2 source identities and dates
GlobalRPh RX List - KIVEXAGlobalRPh-hosted RX List | Source revision: April 2018
International KIVEXA 600/300 mg fixed-dose source; not a newly verified U.S. product label.
Read this stored source NIH adult abacavir/lamivudine - U.S.-focused comparatorNIH ClinicalInfo HIV Guidelines | Source revision: Source revision date not established in selected retrieval.
Adult U.S.-focused ABC/3TC fixed-combination guidance used to compare an international KIVEXA source; not proof of KIVEXA U.S. approval.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
renal marker and toxicity
Creatinine transport is not a blanket explanation for kidney injury
An isolated creatinine increase can reflect tubular transport, but diarrhea and dehydration can cause true injury. Severe-renal and dialysis exposure remain unknown.
What to reconcileUse the clinical course and appropriate alternative renal markers; do not assume that every rise is benign.
2 source identities and dates
GlobalRPh RX List - VERZENIOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VERZENIO oral tablets; product-specific breast-cancer indications and companion therapies. This renal summary does not choose an oncology regimen.
Read this stored source DailyMed / VERZENIO exact product labelDailyMed / Eli Lilly and Company | Source revision: 7/2026
VERZENIO oral tablets; product-specific breast-cancer indications and companion therapies. This renal summary does not choose an oncology regimen.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
formulation
A study dose is not this formulation's prescribing dose
The RX renal section cites a study using another abiraterone product.
What to reconcileDo not import the other product's study dose as the YONSA regimen.
1 source identities and dates
GlobalRPh RX List - YonsaGlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval.
YONSA formulation. The cited dialysis study used another abiraterone product.
Read this stored source Source difference identified; final patient-specific adjudication required. Added: vearlier.
multiple adjustment scope
Keep renal, genotype, interaction and study-entry criteria separate
The new mirror summary retains the MDRD table and the distinct trial CrCl exclusion; current official confirmation was not obtained.
What to reconcileDo not compound separate reduction rules or treat a trial-entry exclusion as an approved renal cutoff.
1 source identities and dates
GlobalRPh RX List - CIBINQOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
CIBINQO abrocitinib, preserving the existing adult record; no age-eligibility expansion is inferred from this renal-only recheck.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.9.
boundary and source conflict
Exact CrCl 30: the contraindication must not be hidden
The original GlobalRPh section prints a below-30 contraindication. The RX mirror explicitly includes 30 in its contraindication while also printing 30-50 in the reduced-dose band.
What to reconcileDo not use the overlapping band as permission at exactly 30. Keep the explicit contraindication visible and obtain current product-specific adjudication.
2 source identities and dates
GlobalRPh RX List - CAMPRALGlobalRPh-hosted RX List | Source revision: 8/2014
CAMPRAL 333 mg delayed-release oral tablets for maintenance of alcohol abstinence with psychosocial support; not treatment of acute withdrawal.
Read this stored source Preserved original GlobalRPh materialGlobalRPh | Source revision: Not established
Historical original source; not revalidated by this note.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
qualitative restriction
A qualitative contraindication is still actionable information
Marked kidney dysfunction is a contraindication in this source, but no numeric cutoff is defined. Dialyzability is discussed in overdose management.
What to reconcileDo not invent a cutoff, borrow another formulation's instructions or turn overdose information into routine dialysis dosing.
1 source identities and dates
GlobalRPh RX List - acetazolamide tabletsGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Acetazolamide oral tablets in the selected historical product mirror; not injection or an extended-release product.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
restriction and incomplete schedule
Two renal exclusion measures and an incomplete further reduction
The source uses both serum-creatinine and CrCl restrictions. It does not supply a complete stepwise regimen as renal function worsens.
What to reconcileKeep both exclusion measures and blood-count precautions. Do not infer the next dose or dialysis supplement.
1 source identities and dates
GlobalRPh RX List - LITHOSTATGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
LITHOSTAT oral adjunct for chronic urea-splitting urinary infection. Source eligibility exclusions, including suitability for definitive treatment, remain essential.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
biomarker and evidence limit
An observed biomarker change is not an unrestricted renal regimen
The source describes an early reversible biomarker pattern and a broad PK statement, without a numerical dialysis dosing schedule.
What to reconcileAssess progressive renal changes; do not import another drug's transport mechanism or a universal acceptable creatinine change.
2 source identities and dates
GlobalRPh RX List - ATTRUBYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ATTRUBY oral tablets for transthyretin amyloid cardiomyopathy. The selected finding is a biomarker/PK qualification, not a dialysis dosing protocol.
Read this stored source DailyMed / ATTRUBY exact product labelDailyMed / BridgeBio Pharma, Inc. | Source revision: 6/2026
ATTRUBY oral tablets for transthyretin amyloid cardiomyopathy. The selected finding is a biomarker/PK qualification, not a dialysis dosing protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
professional protocol difference
Severe impairment: label evidence gap versus eviQ full-dose guidance
The label mirror cannot recommend a dose below CrCl 30. The metastatic breast eviQ protocol permits full dose in severe indexed-eGFR bands, including below 15 without KRT. This is both an evidence-position difference and a renal-measure difference.
What to reconcileReconcile oncology indication, treatment intent, renal measure and KRT with oncology/nephrology. Do not describe eviQ as filling the label gap through proven independent trials.
2 source identities and dates
GlobalRPh RX List - KADCYLAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Intravenous ado-trastuzumab emtansine; not trastuzumab or trastuzumab deruxtecan.
Read this stored source eviQ metastatic breast trastuzumab emtansine - kidney guidanceeviQ / Cancer Institute NSW | Source revision: Source revision date not established in selected retrieval.
Australian metastatic breast cancer protocol; institutional/consensus-derived perspective, not a U.S. label replacement.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
renal measure and toxicity
Indexed MDRD eGFR and diarrhea management are separate decisions
The starting-dose band uses indexed MDRD eGFR; new diarrhea-related renal injury follows the separate toxicity pathway.
What to reconcileConfirm the source measure and reassess toxicity even after selecting the appropriate baseline renal dose.
2 source identities and dates
GlobalRPh RX List - GILOTRIFGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
GILOTRIF tablets for its defined NSCLC indications. Baseline renal dosing and treatment-emergent toxicity modifications are distinct.
Read this stored source DailyMed / GILOTRIF exact product labelDailyMed / Boehringer Ingelheim Pharmaceuticals, Inc. | Source revision: 4/2022
GILOTRIF tablets for its defined NSCLC indications. Baseline renal dosing and treatment-emergent toxicity modifications are distinct.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
baseline versus toxicity
No baseline adjustment does not cancel renal-toxicity stopping rules
A studied baseline CrCl range does not remove the separate Grade 3 interruption and Grade 4 discontinuation instructions.
What to reconcileAssess severity and recovery before resuming; do not dismiss renal injury as a harmless creatinine effect.
1 source identities and dates
GlobalRPh RX List - ALECENSAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ALECENSA oral capsules for its ALK-positive NSCLC indications; selected baseline-renal and treatment-toxicity findings.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
legacy source versus titrated maintenance
Starting dose, maintenance dose and indication must remain separate
Retained GlobalRPh text includes older CrCl-based ceilings. The retrieved RX gout table specifies lower initiation doses without band-specific maxima; the 2020 ACR guideline supports monitored titration to target, including in CKD.
What to reconcileDo not silently blend old ceilings, new starting doses or cancer-therapy dialysis rows. Reconcile the intended gout regimen, source date and renal measure with a clinician.
3 source identities and dates
GlobalRPh RX List - ZYLOPRIMGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oral allopurinol; this source distinguishes gout initiation from cancer-therapy hyperuricemia. It is not an IV ALOPRIM regimen.
Read this stored source 2020 ACR gout guideline - initiation versus titrated maintenanceAmerican College of Rheumatology / Arthritis & Rheumatology | Source revision: 2020
2020 ACR gout guideline; urate-lowering treatment selection and titration, not cancer-therapy or dialysis-specific dosing.
Read this stored source Preserved original GlobalRPh materialGlobalRPh | Source revision: Not established
Historical original source; not revalidated by this note.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
source scope and renal guidance
Before use: Allopurinol
Gout initiation and cancer-associated hyperuricemia have different renal tables in the same label. The dialysis schedule belongs to the cancer indication, not a universal gout regimen.
What to reconcileSelect the indication first. An initial low gout dose is not an eGFR-specific maintenance ceiling.
1 source identities and dates
Allopurinol tablets - Aurobindo indication-specific renal tablesDailyMed / NLM exact product labeling | Source revision: 5/2024
Adults; gout initiation versus cancer-therapy hyperuricemia, not interchangeable indications.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
route indication and age
The adult cancer-therapy renal table is not a gout or pediatric table
ALOPRIM provides a distinct IV adult renal/dialysis table. Severe-renal and dialysis pediatric treatment was not studied.
What to reconcileKeep route, cancer-therapy indication and age scope visible. Check the complete infusion instructions.
1 source identities and dates
GlobalRPh RX List - ALOPRIMGlobalRPh-hosted RX List | Source revision: 2/2022
ALOPRIM IV for cancer-therapy-associated uric-acid elevations when oral treatment cannot be tolerated. The numerical renal table is for adults.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
source scope and renal guidance
Before use: Allopurinol - ALOPRIM intravenous infusion
IV cancer-supportive dosing remains separate from oral gout initiation. This is a generic IV label, not a freshly reconciled ALoprim branded preparation monograph.
What to reconcileKeep indication, IV product and total daily units attached; confirm exact vial preparation separately.
1 source identities and dates
Allopurinol for injection - exact generic IV labelDailyMed / NLM exact product labeling | Source revision: 10/2022
Adults with cancer-therapy hyperuricemia who cannot tolerate oral therapy; IV formulation.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
formulation scope
NESINA: single-agent renal dosing is not combination eligibility
Alogliptin renal doses and HD timing do not determine eligibility for an alogliptin/metformin fixed combination. Peritoneal dialysis remains unstudied.
What to reconcileCheck every component and the dialysis modality before applying the single-agent schedule.
1 source identities and dates
GlobalRPh RX List - NESINAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Alogliptin - NESINA tablets; selected source sections, not a full prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.